Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 168

1.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Apr;103(4):e158-e161. doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21. No abstract available.

2.

Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

Walters DK, Arendt BK, Tschumper RC, Wu X, Jelinek DF.

Exp Hematol. 2018 Jan;57:42-49.e1. doi: 10.1016/j.exphem.2017.09.010. Epub 2017 Oct 13.

PMID:
29030084
3.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. doi: 10.1158/1078-0432.CCR-16-3100. Epub 2017 May 23.

PMID:
28536306
4.

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD.

Br J Haematol. 2017 Jul;178(1):99-105. doi: 10.1111/bjh.14647. Epub 2017 Apr 7.

5.

Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.

Bergen HR 3rd, Dasari S, Dispenzieri A, Mills JR, Ramirez-Alvarado M, Tschumper RC, Jelinek DF, Barnidge DR, Murray DL.

Clin Chem. 2016 Jan;62(1):243-51. doi: 10.1373/clinchem.2015.242651. Epub 2015 Oct 1.

6.

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD.

Cancer. 2015 Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30.

7.

The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, Almada LL, Elsawa SF, Knudson RA, Law ME, Ketterling RP, Cunningham JM, Wu Y, Maurer MJ, O'Byrne MM, Cerhan JR, Slager SL, Link BK, Porcher JC, Grote DM, Jelinek DF, Dogan A, Ansell SM, Fernandez-Zapico ME, Feldman AL.

Blood. 2015 May 14;125(20):3118-27. doi: 10.1182/blood-2014-05-578575. Epub 2015 Apr 1.

8.

Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies.

Dasari S, Theis JD, Vrana JA, Meureta OM, Quint PS, Muppa P, Zenka RM, Tschumper RC, Jelinek DF, Davila JI, Sarangi V, Kurtin PJ, Dogan A.

J Proteome Res. 2015 Apr 3;14(4):1957-67. doi: 10.1021/acs.jproteome.5b00015. Epub 2015 Mar 20.

PMID:
25734799
9.

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, Byrd JC, Grever MR.

Leuk Lymphoma. 2015;56(11):3031-7. doi: 10.3109/10428194.2015.1023800. Epub 2015 Mar 30.

10.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Blood. 2015 Jan 29;125(5):856-9. doi: 10.1182/blood-2014-09-600874. Epub 2014 Dec 17.

11.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH.

Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.

12.

Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia.

Xochelli A, Agathangelidis A, Kavakiotis I, Minga E, Sutton LA, Baliakas P, Chouvarda I, Giudicelli V, Vlahavas I, Maglaveras N, Bonello L, Trentin L, Tedeschi A, Panagiotidis P, Geisler C, Langerak AW, Pospisilova S, Jelinek DF, Oscier D, Chiorazzi N, Darzentas N, Davi F, Ghia P, Rosenquist R, Hadzidimitriou A, Belessi C, Lefranc MP, Stamatopoulos K.

Immunogenetics. 2015 Jan;67(1):61-6. doi: 10.1007/s00251-014-0812-3. Epub 2014 Nov 12.

PMID:
25388851
13.

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.

Lancet Haematol. 2014 Nov;1(2):e74-84. doi: 10.1016/S2352-3026(14)00005-2. Epub 2014 Nov 3.

PMID:
27030157
14.

Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

Barnidge DR, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich MA, Tschumper RC, Jelinek DF, Snyder MR, Dispenzieri A, Katzmann JA, Murray DL.

J Proteome Res. 2014 Nov 7;13(11):5198-205. doi: 10.1021/pr5005967. Epub 2014 Aug 26.

PMID:
25134970
15.

Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation.

Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF.

Oncotarget. 2014 Jul 30;5(14):5686-99.

16.

Eosinophil purification from human bone marrow.

Wong TW, Jelinek DF.

Methods Mol Biol. 2014;1178:21-7. doi: 10.1007/978-1-4939-1016-8_3.

PMID:
24986604
17.

TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells.

Wu X, Blackburn PR, Tschumper RC, Ekker SC, Jelinek DF.

Blood Cancer J. 2014 May 9;4:e210. doi: 10.1038/bcj.2014.32.

18.

Eosinophils regulate peripheral B cell numbers in both mice and humans.

Wong TW, Doyle AD, Lee JJ, Jelinek DF.

J Immunol. 2014 Apr 15;192(8):3548-58. doi: 10.4049/jimmunol.1302241. Epub 2014 Mar 10.

19.

Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.

Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, Kay NE, Shanafelt TD.

Cancer Genet. 2014 Jan-Feb;207(1-2):19-30. doi: 10.1016/j.cancergen.2014.01.004. Epub 2014 Jan 17.

20.

Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.

Barnidge DR, Tschumper RC, Theis JD, Snyder MR, Jelinek DF, Katzmann JA, Dispenzieri A, Murray DL.

J Proteome Res. 2014 Apr 4;13(4):1905-10. doi: 10.1021/pr5000544. Epub 2014 Mar 5.

PMID:
24552626

Supplemental Content

Loading ...
Support Center